The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs

被引:28
|
作者
Schwebel, Herve J. [1 ]
van Hoogevest, Peter [1 ]
Leigh, Mathew L. S. [1 ]
Kuentz, Martin [2 ]
机构
[1] Phares AG, Muttenz, Switzerland
[2] Univ Appl Sci NW Switzerland, Inst Pharma Technol, CH-4132 Muttenz, Switzerland
关键词
Poorly soluble drugs; biorelevant media; FeSSIF; FaSSIF; apparent solubilizing capacity; BIORELEVANT DISSOLUTION MEDIA; HUMAN GASTROINTESTINAL-TRACT; BILE-SALT; FENOFIBRATE; FORMULATION; ABSORPTION; BIOAVAILABILITY; PREDICTION; LECITHIN; MICELLE;
D O I
10.3109/10837451003664099
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug solubility testing in biorelevant media has become an indispensable tool in pharmaceutical development. Despite this importance, there is still an incomplete understanding of how poorly soluble compounds interact with these media. The aim of this study was to apply the concept of the apparent solubilization capacity to fasted and fed state simulated intestinal fluid (FaSSIF and FeSSIF, respectively). A set of non-ionized poorly soluble compounds was studied in biorelevant media prepared from an instantly dissolving complex (SIF (TM) Powder) at 37 degrees C. The values of the solubilization capacity were different between FaSSIF and FeSSIF but correlated. Drug inclusion into the mixed micelles was highly specific for a given compound. The ratio of the FeSSIF to FaSSIF solubility was in particular considered and discussed in terms of the apparent solubilizing capacity. The apparent solubilization concept appears to be useful for the interpretation of biorelevant solubility tests. Further studies are needed to explore acidic and basic drugs.
引用
收藏
页码:278 / 286
页数:9
相关论文
共 50 条
  • [31] Lipophilic Formulations for Increasing Bioavailability of Poorly Water-Soluble Drugs
    Franc, Ales
    Vetchy, David
    Smilkova, Ladislava
    Rabiskova, Miloslava
    Kratochvil, Bohumil
    CHEMICKE LISTY, 2012, 106 (01): : 3 - 9
  • [32] HYDROSOLS - ALTERNATIVES FOR THE PARENTERAL APPLICATION OF POORLY WATER-SOLUBLE DRUGS
    GASSMANN, P
    LIST, M
    SCHWEITZER, A
    SUCKER, H
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1994, 40 (02) : 64 - 72
  • [33] Solubilization of Poorly Water-soluble Drugs with Amphiphilic Phospholipid Polymers
    Yoshie, Kensuke
    Ishiharab, Kazuhiko
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2023, 143 (09): : 745 - 756
  • [34] Microcrystals for dissolution rate enhancement of poorly water-soluble drugs
    Rasenack, N
    Hartenhauer, H
    Müller, BW
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 254 (02) : 137 - 145
  • [35] The use of zein in the controlled release of poorly water-soluble drugs
    Tran, Phuong H. L.
    Dian, Wei
    Lee, Beom-Jin
    Tran, Thao T. D.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 566 : 557 - 564
  • [36] Solubilization and Controlled Release Strategy of Poorly Water-Soluble Drugs
    Pena, M. A.
    PHARMACEUTICALS, 2022, 15 (11)
  • [37] Disposition of lipid-based formulation in the intestinal tract affects the absorption of poorly water-soluble drugs
    Iwanaga, K
    Kushibiki, T
    Miyazaki, M
    Kakemi, M
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (03) : 508 - 512
  • [38] Solubilization of poorly water-soluble drug carbamezapine in Pluronic® micelles: Effect of molecular characteristics, temperature and added salt on the solubilizing capacity
    Kadam, Yogesh
    Yerramilli, Usha
    Bahadur, Anita
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2009, 72 (01) : 141 - 147
  • [39] Postprandial Changes in Solubilizing Capacity of Human Intestinal Fluids for BCS Class II Drugs
    Sarah Clarysse
    Dimitrios Psachoulias
    Joachim Brouwers
    Jan Tack
    Pieter Annaert
    Guus Duchateau
    Christos Reppas
    Patrick Augustijns
    Pharmaceutical Research, 2009, 26 : 1456 - 1466
  • [40] Postprandial Changes in Solubilizing Capacity of Human Intestinal Fluids for BCS Class II Drugs
    Clarysse, Sarah
    Psachoulias, Dimitrios
    Brouwers, Joachim
    Tack, Jan
    Annaert, Pieter
    Duchateau, Guus
    Reppas, Christos
    Augustijns, Patrick
    PHARMACEUTICAL RESEARCH, 2009, 26 (06) : 1456 - 1466